Clinical Trial Update: Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial [Phase 1, Phase 2]

View source ↗

Summary

Rollover extension study for subjects who participated in an ASP2215 (gilteritinib) trial, enrolling patients with acute myeloid leukemia; status completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Advanced Solid Tumors, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-08-16